Table 4.
Incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis according to risk factors (n = 665) n (%)
| Risk factors | Indomethacin group | Control group | P value |
| Age < 50 yr (n = 104) | 5/57 (8.77) | 6/47 (12.76) | 0.365 |
| Female gender (n = 426) | 16/214 (7.47) | 19/212 (8.96) | 0.576 |
| BMI > 25 (n = 362) | 12/191 (6.28) | 10/171 (5.85) | 0.862 |
| Duration of ERCP > 20 min (n = 211) | 8/111 (7.2) | 7/100 (7.0) | 0.580 |
| Non-dilated bile duct (n = 299) | 10/158 (6.33) | 11/141 (7.8) | 1.000 |
| Pancreatic duct opacification (n = 463) | 20/246 (8.13) | 20/217 (9.21) | 0.263 |
| EST biliary (n = 443) | 14/224 (6.25) | 14/219 (6.4) | 0.951 |
| EST pancreatic/double (n = 48) | 4/20 (20.0) | 5/28 (17.86) | 0.560 |
| Difficult cannulation (n = 116) | 4/64 (6.25) | 6/52 (11.54) | 0.478 |
| Gallstone extraction (n = 165) | 3/82 (3.66) | 5/83 (6.02) | 0.451 |
| Bile duct dilatation (n = 22) | 1/11 (9.1) | 2/11 (18.2) | 0.537 |
| Biliary plastic stent placement (n = 75) | 4/35 (11.43) | 3/40 (7.5) | 0.580 |
There were no statistically significant differences. BMI: Body mass index; EST: Endoscopic sphincterotomy; ERCP: Endoscopic retrograde cholangiopancreatography.